SCHEMBL16029352

SCHEMBL16029352

CCc1coc(CSc2nc3c(c(=O)n(C)c(=O)n3C)n2Cc2ccc(F)cc2)n1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.63
NPSR1 Q6W5P4 3/20 0.63
POLB P06746 2/20 0.63
HPGD P15428 1/20 0.63
GAA P10253 1/20 0.62
TSHR P16473 5/20 0.60
SMN1; SMN2 Q16637 3/20 0.58
LMNA P02545 2/20 0.58
MAOA P21397 2/20 0.58
MAOB P27338 2/20 0.58
MAPT P10636 3/20 0.57
TP53 P04637 3/20 0.57
RXFP1 Q9HBX9 1/20 0.57
HTT P42858 2/20 0.56
PLD3 Q8IV08 1/20 0.54
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
MAPK1 P28482 2/20 0.52
GFER P55789 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16029403 0.92 ALDH1A1 (0.70) ALDH1A1NPSR1POLBHPGDGAA
SCHEMBL16029479 0.92 TSHR (0.70) ALDH1A1NPSR1POLBHPGDGAA
SCHEMBL16029277 0.91 ALDH1A1 (0.58) ALDH1A1NPSR1POLBHPGDGAA
SCHEMBL16030036 0.89 ALDH1A1 (0.55) ALDH1A1NPSR1POLBHPGDGAA
SCHEMBL16029504 0.89 ALDH1A1 (0.56) ALDH1A1NPSR1POLBHPGDGAA
SCHEMBL16029556 0.88 PLD3 (0.56) ALDH1A1NPSR1POLBHPGDGAA
SCHEMBL16029321 0.88 ALDH1A1 (0.55) ALDH1A1NPSR1POLBHPGDGAA
SCHEMBL16029974 0.88 MAPT (0.53) ALDH1A1NPSR1POLBHPGDGAA
SCHEMBL19560555 0.86 ALDH1A1 (0.58) ALDH1A1NPSR1POLBHPGDGAA
SCHEMBL16029656 0.86 MAOA (0.60) ALDH1A1NPSR1POLBHPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2970316-B1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES INC (US) 2017-11-08 EP disclosed
EP-2970316-B1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES INC (US) 2017-11-08 EP disclosed
US-20160145257-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES, INC. 2016-05-26 US disclosed
US-20160145257-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES, INC. 2016-05-26 US disclosed
US-20160145257-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES, INC. 2016-05-26 US disclosed
WO-2014152287-A9 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES, INC. (US) 2015-04-23 WO disclosed
WO-2014152287-A2 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES, INC. (US) 2014-09-25 WO disclosed
US-20140275528-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES, INC. (US) 2014-09-18 US disclosed
US-20140275528-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES, INC. (US) 2014-09-18 US disclosed
US-20140275528-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES, INC. (US) 2014-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160145257-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF TRPC5, TRPC7, TRPC4 ALDH1A1 1647/4885NPSR1 836/4885POLB 3162/4885
US-20140275528-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF TRPC5, TRPC7, TRPC4 ALDH1A1 1647/4885NPSR1 836/4885POLB 3162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.